Daniel Dupret
President bij AzurRx BioPharma SAS
Profiel
Daniel Dupret was the founder of Appligene Oncor SA, founded in 1985, where he held the title of President & Chief Executive Officer until 1998, and Protéus SA, founded in 1998, where he held the title of President & Chief Executive Officer until 2007.
Currently, he is the President of AzurRx BioPharma SAS since 2008.
He was the Chief Scientific Officer of First Wave Biopharma, Inc. from 2014 to 2019 and the President of the University of Nimes from 2003 to 2007.
Dr. Dupret has an undergraduate degree from the Institut National des Sciences Appliquées de Lyon and a doctorate from the University of Strasbourg.
Actieve functies van Daniel Dupret
| Bedrijven | Functie | Begin |
|---|---|---|
AzurRx BioPharma SAS
 AzurRx BioPharma SAS Miscellaneous Commercial ServicesCommercial Services Part of First Wave Biopharma, Inc., AzurRx BioPharma SAS is a French company that provides bioscience and biotechnology research and development services. The company is based in Langlade, France. AzurRx BioPharma was acquired by First Wave Biopharma, Inc. from Protea Biosciences Group, Inc. on June 13, 2014 for $2.20 million. | President | 01-10-2008 |
Eerdere bekende functies van Daniel Dupret
| Bedrijven | Functie | Einde |
|---|---|---|
| ENTERO THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-07-2019 |
Protéus SA
 Protéus SA BiotechnologyHealth Technology Protéus SA discovers, engineers, and manufactures proteins for industrial applications. It operates as a biotechnology company that focuses on the discovery, engineering and manufacturing of proteins of industrial interest, and on the development of protein-based bioprocesses. The company was founded on August 11, 1998 and is headquartered in Paris, France. | Algemeen Directeur | 01-01-2007 |
| University of Nimes | President | 01-01-2007 |
Appligene Oncor SA
 Appligene Oncor SA Pharmaceuticals: OtherHealth Technology Part of Valiant Co., Ltd., Appligene Oncor SA is a French company that specializes in medicinal chemicals and botanical products. The company is based in Illkirch Graffenstaden, France. The company was founded by Daniel Dupret. Appligene Oncor was acquired by Quantum Biotechnologies, Inc. on February 17, 1999 for $1.24 million. | Algemeen Directeur | 01-01-1998 |
Opleiding van Daniel Dupret
| Institut National des Sciences Appliquées de Lyon | Undergraduate Degree |
| University of Strasbourg | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ENTERO THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Appligene Oncor SA
Appligene Oncor SA Pharmaceuticals: OtherHealth Technology Part of Valiant Co., Ltd., Appligene Oncor SA is a French company that specializes in medicinal chemicals and botanical products. The company is based in Illkirch Graffenstaden, France. The company was founded by Daniel Dupret. Appligene Oncor was acquired by Quantum Biotechnologies, Inc. on February 17, 1999 for $1.24 million. | Health Technology |
Protéus SA
Protéus SA BiotechnologyHealth Technology Protéus SA discovers, engineers, and manufactures proteins for industrial applications. It operates as a biotechnology company that focuses on the discovery, engineering and manufacturing of proteins of industrial interest, and on the development of protein-based bioprocesses. The company was founded on August 11, 1998 and is headquartered in Paris, France. | Health Technology |
AzurRx BioPharma SAS
AzurRx BioPharma SAS Miscellaneous Commercial ServicesCommercial Services Part of First Wave Biopharma, Inc., AzurRx BioPharma SAS is a French company that provides bioscience and biotechnology research and development services. The company is based in Langlade, France. AzurRx BioPharma was acquired by First Wave Biopharma, Inc. from Protea Biosciences Group, Inc. on June 13, 2014 for $2.20 million. | Commercial Services |
| University of Nimes |
